Overview

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

Status:
Completed

Trial end date:
2017-03-01

Target enrollment:

Participant gender:

Summary

This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.

Phase:

N/A

Details

Lead Sponsor:

MDbackline, LLC

Collaborator:

Alcon Research

Treatments:

Ketorolac
Ketorolac Tromethamine
Nepafenac
Ophthalmic Solutions
Tetrahydrozoline